Tenet Reports Strong Fourth Quarter and FY 2024 Results; Provides 2025 Financial Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Tenet Healthcare (THC) PT Lowered to $185 at Raymond James, 'Selloff After Quarter is Perplexing — Creates Attractive Entry Point Despite Policy Risks'
February 13, 2025 8:45 AM ESTRaymond James analyst John Ransom lowered the price target on Tenet Healthcare (NYSE: THC) to $185.00 (from $195.00) while maintaining a Outperform rating.
The analyst comments "We reiterate our Outperform rating on shares of THC while lowering our price target to $185 (8.5x 2026 EBITDA ex-NCI) following 4Q24 results that were slightly... More
